Interpreting nonrandomized clinical trial data in low-grade sarcoma: Differentiating clinical benefit from indolent disease is key Correspondence

  


Authors: Rosenbaum, E.; Movva, S.; Kelly, C.
Title: Interpreting nonrandomized clinical trial data in low-grade sarcoma: Differentiating clinical benefit from indolent disease is key
Keywords: treatment response; letter; tumor volume; histology; sarcoma; chondrosarcoma; olaparib; clinical trial (topic); tumor metabolism; epithelioid hemangioendothelioma; nivolumab; recombination repair; human
Journal Title: JCO Precision Oncology
Volume: 6
ISSN: 2473-4284
Publisher: American Society of Clinical Oncology  
Date Published: 2022-06-08
Start Page: e2200092
Language: English
DOI: 10.1200/po.22.00092
PUBMED: 35675574
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85133657357&doi=10.1200%2fPO.22.00092&partnerID=40&md5=d43930027abfb6cde2914d8247251bf1
Notes: Letter -- Export Date: 1 August 2022 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Ciara Marie Kelly
    89 Kelly
  2. Evan Rosenbaum
    52 Rosenbaum
  3. Sujana Movva
    46 Movva
Related MSK Work